**In the Claims:**

1. (Previously presented) A method of treatment of a cholesterol-associated tumor comprising administering a therapeutically effective amount of an azetidinone-based cholesterol absorption inhibitor to a patient wherein the patient exhibits a cholesterol-associated tumor.

2. (Previously presented) The method of treatment of a cholesterol-associated tumor according to claim 1 wherein the azetidinone-based cholesterol absorption inhibitor is selected from the group consisting of ezetimibe, SCH 48461 and SCH 58053.

3. (Previously presented) The method of treatment of a cholesterol-associated tumor according to claim 2 wherein the azetidinone-based cholesterol absorption inhibitor is ezetimibe or a stereoisomeric mixture thereof, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomer thereof, or a prodrug of such compound, mixture or isomer thereof, or a pharmaceutically acceptable salt of the compound, mixture, isomer or prodrug.

4. (Previously presented) The method of treatment of a cholesterol-associated tumor according to claim 1 wherein the azetidinone-based cholesterol absorption inhibitor is selected from the group consisting of ezetimibe, the phenolic glucuronide of ezetimibe, SCH 48461 and SCH 58053.

5. (Previously presented) The method of treatment of a cholesterol-associated tumor according to claim 1 wherein the cholesterol-associated tumor is selected from the group consisting of benign prostatic hypertrophy, benign breast tumor, benign endometrial tumor, and benign colon tumor.

6. (Previously presented) The method of treatment of a cholesterol-associated tumor according to claim 1 wherein the cholesterol-associated tumor is selected from the group consisting of malignant prostate tumor, breast cancer tumor, endometrial cancer tumor, and colon cancer tumor.

7. (Previously presented) The method of treatment of a cholesterol-associated tumor according to claim 5 wherein the azetidinone-based cholesterol absorption inhibitor is ezetimibe and/or at least one pharmacologically active analog thereof.

8. (Previously presented) The method of treatment of a cholesterol-associated tumor according to claim 6 wherein the azetidinone-based cholesterol absorption inhibitor is ezetimibe and/or at least one pharmacologically active analog thereof.

9. (Previously presented) The method of treatment of a cholesterol-associated tumor according to claim 7 wherein a therapeutically effective amount is between about 0.1 to about 30 mg/kg of body weight daily.

10. (Previously presented) The method of treatment of a cholesterol-associated tumor according to claim 8 wherein a therapeutically effective amount is between about 0.1 to about 30mg/kg of body weight daily.

11. (Previously presented) A method of treatment of a cholesterol-associated tumor comprising co-administering a therapeutically effective amount of an azetidinone-based cholesterol absorption inhibitor and at least one other anticancer agent to a patient wherein the patient exhibits a cholesterol-associated tumor.

12. (Previously presented) The method of treatment according to claim 11 wherein the azetidinone-based cholesterol absorption inhibitor is ezetimibe and its analogs.

13. (Previously presented) The method of treatment according to claim 12 wherein at least one other anticancer agent is selected from the group consisting of a steroidal antiandrogen, a non steroidal antiandrogen, an estrogen, diethylstilbestrol, a conjugated estrogen, a selective estrogen receptor modulator (SERM), a taxane, and a LHRH analog.

14. (Previously presented) The method of treatment according to claim 13 wherein the non steroidal antiandrogen is selected from the group consisting of finasteride (PROSCAR®), flutamide (4'-nitro-3'-trifluoromiethyl isobutyranilide), bicalutamide (CASODEX®), and nilutamide.

15. (Previously presented) The method of treatment according to claim 13 wherein the SERM is selected from the group consisting of tamoxifen, raloxifene, droloxifene, and idoxifene.

16. (Previously presented) The method of treatment according to claim 13 wherein the taxane is selected from the group consisting of paclitaxel (TAXOL®), and docetaxel (TAXOTERE®).

17. (Previously presented) The method of treatment according to claim 13 wherein the LHRH analog is selected from the group consisting of goserelin acetate (ZOLADEX®), and leuprolide acetate (LUPRON®).

18. (Currently amended) A composition for the treatment of a cholesterol-associated tumor comprising a therapeutically effective amount of an azetidinone-based cholesterol absorption inhibitor and at least one other anticancer agent selected from the group consisting of a steroidal antiandrogen, a non steroidal antiandrogen, an estrogen, diethylstilbestrol, a conjugated estrogen, a selective estrogen receptor modulator (SERM), a taxane, and a LHRH analog.

19. (Previously presented) The composition according to claim 18 wherein the azetidinone-based cholesterol absorption inhibitor is ezetimibe.

20. (Cancel)

21. (Currently amended) The composition according to claim [[20]] 19 wherein the non-steroidal antiandrogen is selected from the group consisting of finasteride (PROSCAR®), flutamide (4'-nitro-3'-trifluorormethyl isobutyranilide), bicalutamide (CASODEX®), and nilutamide.

22. (Currently amended) The composition according to claim [[20]] 19 wherein the SERM is selected from the group consisting of tamoxifen, raloxifene, droloxifene, and idoxifene.

23. (Currently amended) The composition according to claim [[20]] 19 wherein the taxane is selected from the group consisting of paclitaxel (TAXOL®), and docetaxel (TAXOTERE®).

24. (Currently amended) The composition according to claim [[20]] 19 wherein the LHRH analog is selected from the group consisting of goserelin acetate (ZOLADEX®), and leuprolide acetate (LUPRON®).

25. (Currently amended) An article of manufacture comprising a container, instructions, and a composition, wherein the composition comprises a therapeutically effective amount of an azetidinone-based cholesterol absorption inhibitor and at least one other anticancer agent, and the instructions are for the administration of the composition for the treatment of a cholesterol-associated tumor, wherein at least one other anticancer agent is selected from the group consisting of a steroidal antiandrogen, a non-steroidal antiandrogen, an estrogen, diethylstilbestrol, a conjugated estrogen, a selective estrogen receptor modulator (SERM), a taxane, and a LHRH analog.

26. (Previously presented) The article of manufacture according to claim 25 wherein the azetidinone-based cholesterol absorption inhibitor is ezetimibe and/or at least one pharmacologically active analog thereof.

27. (Previously presented) The article of manufacture according to claim 26 wherein the instructions are for the administration of the composition for the treatment of a tumor selected from the group consisting of prostatic hypertrophy (prostate tumor), breast tumor, endometrial tumor, and colon tumor.

28-29. (Cancel)

* * *